• Episode 2 - AZALEA TIMI TRIAL 2025 AFIB

  • Feb 25 2025
  • Durée: 12 min
  • Podcast

Episode 2 - AZALEA TIMI TRIAL 2025 AFIB

  • Résumé

  • Episode 2: AZALEA-TIMI 71 – Factor XI Inhibition vs. Rivaroxaban in Atrial Fibrillation

    The AZALEA-TIMI 71 Trial assesses the safety and efficacy of Abelacimab, a Factor XI inhibitor, compared to Rivaroxaban, a Factor Xa inhibitor, in atrial fibrillation patients at moderate-to-high risk of stroke. This episode covers:

    • How Factor XI inhibition differs from traditional anticoagulation
    • Study outcomes on bleeding risk and stroke prevention
    • Clinical implications for AF management
    • The potential of Factor XI inhibitors as the future of anticoagulation
    Voir plus Voir moins

Ce que les auditeurs disent de Episode 2 - AZALEA TIMI TRIAL 2025 AFIB

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.